Explore ViiV Healthcare

I am a
  • HCP
  • person living with HIV
  • NGO or patient group
  • job seeker
  • member of the public
  • academia / entrepreneur
  • media
...looking for
  • information about VHC medicines
  • clinical data and insights on VHC medicines
  • Independent Medical Education
  • medicines in development
  • how VHC is advancing HIV treatment and care
...looking for
  • information about VHC medicines
  • information and support about living with HIV
  • how to report a side effect
  • news and stories from ViiV Healthcare
...looking for
  • funding / grants
  • ViiV Healthcare's approach to partnerships
  • how ViiV Healthcare works with NGOs
  • news and stories from ViiV Healthcare
  • connect with ViiV Healthcare's community
...looking for
  • job opportunities
  • information about ViiV Healthcare
  • ViiV Healthcare's office locations
  • news and stories from ViiV Healthcare
...looking for
  • who are ViiV Healthcare
  • corporate ethics & compliance
  • news and stories from ViiV Healthcare
...looking for
  • opportunities to partner with ViiV Healthcare
  • information on ViiV Healthcare's Innovation Unit
  • news and stories from ViiV Healthcare
...looking for
  • press releases
  • ViiV Healthcare's Leadership
  • news and stories from ViiV Healthcare

Dovato

DOVATO (dolutegravir/lamivudine) is listed on the Australian Register of Therapeutic Goods (ARTG).

DOVATO is indicated for the treatment of HIV-1 infection in antiretroviral treatment-naïve adults and adolescents (from 12 years of age weighing at least 40 kg) who have no known or suspected resistance to either antiretroviral component.

PBS Information: This product is listed on the PBS as a section 100 item. Refer to PBS schedule for full authority information.

Resources

For patients:

For HCPs: